Unexpected Adverse Effect of Clofarabine Plus Cytosine Arabinoside: Bronze Hyperpigmentation

Aysun Şenturk Yikilmaz¹, Sema Akinci², Sule Mine Bakanay¹, Kamile Silay³*, Imdat Dilek¹

¹Department of Hematology, Yıldırım Beyazit University, Turkey
²Department of Hematology, Atatürk Training and Research Hospital, Ankara, Turkey
³Department of Geriatrics, Yıldırım Beyazit University, Turkey

Submission: December 15, 2018; Published: March 20, 2018

*Corresponding author: Kamile Silay, Department of Geriatrics, Yıldırım Beyazit University, Turkey, Email: kamilesilay@hotmail.com

Abstract

Objective: Rare unexpected adverse effect

Background: Skin toxicity in acute myeloid leukemia (AML) is a condition that with a lot of chemotherapy agents [1]. We report a patient with relapsed AML, who developed generalized bronze pigmentation of skin after a second cycle of clofarabine plus high dose Ara-C.

Case Report: In this report, we describe the case of a 74-year-old male with refractory acute myeloid leukemia with skin toxicity as bronze hyperpigmentation, diarrhea, hyperbilirubinemia, and liver toxicity associated with clofarabine treatment.

Conclusions: The side effects of clofarabine in the second course may be more aggressive than the first course. The bronze hyperpigmentation with clofarabine should also be meant to keep in mind.

Keywords: Clofarabine; Bronze hyperpigmentation; Acute myeloid leukemia

Abbreviations: AML: Acute Myeloid Leukemia; HSCT: Hematopoietic Stem Cell Transplantation

Background

Skin toxicity in acute myeloid leukemia (AML) is a condition that with a lot of chemotherapy agents [1]. We report a patient with relapsed AML, who developed generalized bronze pigmentation of skin after a second cycle of clofarabine plus high dose Ara-C.

Case Report

In 2013, a 74-year-old male patient was evaluated because of fatigue and bicytopenia and was diagnosed as AML M4. The patient received the 7+3 induction therapy with Ara-C and idarubicine followed by 3 cycles of high dose Ara-C consolidation. Since the patient had a good performance status and no comorbid conditions, allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning was planned. However, a search for an HLA-matched family or an unrelated donor failed to find a suitable donor. The patient relapsed 11 months after the initial diagnosis. Salvage chemotherapy with clofarabine 40 mg/m²/day and Ara-C 2g/m²/day for five days was administered. Diarrhea began on the second day of the first cycle and stopped on the eleventh day, electrolyte replacement was not required. Transient hyperbilirubinemia with a total bilirubin of 5.9 mg/dl and mild increase in transaminases were observed on the fifth day. The patient became febrile on the fourth day of chemotherapy and was treated with appropriate antibiotics. The patient’s blood counts recovered on the twenty-fourth day and a control bone marrow biopsy before discharge was in hematologic remission. After six weeks, the patient was rehospitalized for a second cycle of clofarabine and Ara-C. Severe diarrhea which required electrolyte replacement and a moderate to severe increase in transaminases (AST/ALT: 425/625 U/I) were observed on the third and the fourth days of the chemotherapy, respectively. On the seventh day of the treatment cycle, the patient developed bronze pigmentation on the whole body surface. The patient had an extended febrile neutropenic period and antifungal therapy was added due to suspected aspergillus infection on thorax CT. However, the patient died of sepsis before recovery of blood counts.

Discussion

Survival of elderly patients with relapsed/refractory AML is low. Allogeneic HSCT with reduced intensity conditioning regimens has increasingly been performed in fit -elderly population. However, not all patients can receive such a curative approach either due to comorbid conditions or lack of an available donor. Clofarabine in combination with Ara-C has been shown
to be effective in elderly patients both as induction and salvage regimen [2]. Clofarabine is a second generation purine analog designed to combine the favorable properties of fludarabine and 2-chlorodeoxyadenosine. Thus, when administered before Ara-C, it might enhance intracellular conversion of Ara-C to its active metabolite Ara-C TP providing better cell killing [3]. In the only randomized phase III study, clofarabine plus Ara-C was compared with Ara-C alone in patients (≥ 55 years) with relapsed/refractory AML and better ORR and EFS with clofarabine plus Ara-C was reported. This protocol although did not prolong the OS compared with the Ara-C arm, allowed more patients to proceed to HSCT.

The main grade 3-4 toxicities were myelosuppression, febrile neutropenia, pneumonia and increased transaminases. They also reported skin toxicity mainly as non-specific skin rash or hand-foot syndrome [4]. Ara-C dose in most studies is 1g/m²/day. In our patient, we administered Ara-C 2g/m²/day depending on a report by Tse et al, who demonstrated higher CR rate with Ara-C 2g/m²/ day versus Ara-C 1g/m²/day [5]. Most common adverse events observed with clofarabine containing regimens are diarrhea, liver toxicity, skin rash, hand-foot syndrome, mucous membrane involvement, renal failure, bone marrow suppression [6] (Figures 1 & 2).

Conclusion

To our knowledge, bronze pigmentation of skin after clofarabine plus Ara-C combination has not been reported so far. Besides, increased mortality has been observed especially due to grade 4 myelosuppression and propensity to sepsis. This should be taken into account when administering clofarabine plus Ara-C to elderly AML population. The efficacy and safety of sequential administration of clofarabine plus Ara-C chemotherapy requires further investigation.

References


